Loading companies…
C
CellsBin
United States · Biotech
A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring.
Following disease through individual cells
CellsBin's Scout platform detects and profiles rare cells so researchers can study populations that are difficult to isolate in conventional samples. Its Polaris approach combines rare-cell detection, longitudinal monitoring and single-cell datasets with AI analysis.
The company is developing Insight for blood-based assessment of multiple myeloma. CellsBin is based in Branford, Connecticut, where it operates a CLIA laboratory.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | 108 BioCapital — Lead |
Investors
108 BioCapitalLed Series ACoverage
Sep 22, 2026CellsBin · Series ASimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed